Navigation Links
BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
Date:9/4/2008

otide (MBP8298)

--------------------------

Dirucotide (MBP8298) is a synthetic peptide that consists of 17 amino acids having a sequence identical to that of a portion of human myelin basic protein (MBP). Dirucotide is being developed for the potential treatment of multiple sclerosis (MS), an autoimmune disease caused by immune attack against normal components of the central nervous system. The sequence of dirucotide is associated with the autoimmune process in MS patients with certain immune response genes (HLA types DR2 and/or DR4); MS patients having these genes represent 65 to 75 percent of all MS patients.

The drug's apparent mechanism of action is the induction or restoration of immunological tolerance with respect to ongoing immune attack as a result of high doses of peptide periodically delivered intravenously. The potential benefit of the drug for any individual patient is therefore expected to be related to the role this peptide plays in that patient's immune system. The degree of immunomodulation achieved will depend on the relationship among the peptide, HLA molecules and T cells.

The results of phase II and long-term follow-up treatment of MS patients with MBP8298 (dirucotide), published in 2006 in the European Journal of Neurology (EJN), showed that MBP8298 (dirucotide) safely delayed median time to disease progression for five years (versus placebo) in progressive MS patients with HLA types DR2 and/or DR4. Thus, dirucotide (MBP8298), if approved, has the potential to be used as a tailored therapy for patients genetically determined to express the appropriate HLA molecules.

Dirucotide (MBP8298) is being studied in four late-stage clinical trials:

- MAESTRO-01: A pivotal phase II/III trial for secondary progressive MS

(SPMS) patients in Canada and Europe.

- MAESTRO-02: An open-label safety extension study to MAESTRO-01.

- MAESTRO-03: A pivotal phase III trial for SPMS patients
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
3. BioMS Medical Announces Second Quarter 2008 Results
4. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
5. BioMS Medical to present at BMO Healthcare Conference
6. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
7. BioMS Medical to present at Jefferies Healthcare Conference
8. BioMS Medical to present at 2008 BIO International Convention
9. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
10. BioMS Medical announces first quarter 2008 results
11. BioMs Medical to present at TIDES(R) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015  Merck KGaA, Darmstadt, ... top-quality high-tech products in the healthcare, life science and ... company Nano-C, their development and launch of promising new ... (OPV). Merck KGaA, Darmstadt, Germany , ... OPV sector. Novel derivatives: highly stable, easy ...
(Date:8/3/2015)... 2015   Intrexon Corporation (NYSE: XON ... second quarter 2015 financial results after the market closes ... will host a conference call at 5:30 PM ET ... update. The conference call may be accessed ... asking to join the "Intrexon Corporation Call."  Participants may ...
(Date:7/31/2015)... July 31, 2015 In today,s fast ... help them drive positive health outcomes, improve profitability ... of patient care in their communities. At ThoughtSpot ... and conference, AmerisourceBergen announced a new set of ... Administration Organization and help independent pharmacies endure the ...
(Date:7/30/2015)... ... ... Ralco is honored to announce that it is the primary sponsor of ... 5-9 in Marshall. The Ralco Enrichment Center is an interactive experience where the public ... daily lives. This unique exhibit also features a birthing center for fair goers to ...
Breaking Biology Technology:Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2
... NEW YORK, Sept. 6, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0610872/Industrial-Biotechnology-China-News-1108.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biotechnology In ... break the foreign enterprises, monopoly in the ...
... is invisible it,s at the farthest end of the ... explosives at the airport to designing drugs to diagnosing skin ... Department of Energy,s Lawrence Berkeley National Laboratory (Berkeley Lab) and ... device made of graphene the remarkable form of carbon ...
... , , , , ... AUDIO: This audio file is a brief ... Click here for more information. , ... , , , , ...
Cached Biology Technology:Industrial Biotechnology China News 1108 2Industrial Biotechnology China News 1108 3A whole new light on graphene metamaterials 2A whole new light on graphene metamaterials 3MIABE standard opens up new opportunities in drug discovery 2MIABE standard opens up new opportunities in drug discovery 3
(Date:7/30/2015)... , July 30, 2015 Cellecta, ... for gene function analysis and biomarker discovery, announced ... (sgRNA) Knockout Library targeting all human protein coding ... permanently "knock out" a gene,s function. Cellecta,s new ... high throughput screening tool so that researchers can ...
(Date:7/23/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ... "Global Outlook of the Biometrics Industry 2015 " ... The global biometrics market is likely to witness ... owing to the uptake of multiple technologies available. ... enhances the growth of biometrics in existing applications ...
(Date:7/20/2015)... 2015  Acuity Market Intelligence,s latest research "The ... Commerce and Privacy" forecasts that between 2014 and ... be downloaded to smart mobile devices by 2.2 ... is projected to generate more than $67.9 billion ... forecast period.    "Biometrics is at ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
... associate professor Karen Warkentin, working at the Smithsonian ... that frog embryos at a very early developmental ... eggas reported in the Nov. 7, 2008 issue ... These initial responses to the environment may be ...
... receive all recommended flu vaccine appear to be less likely ... 20,000 children every year. This is according to new ... Rochester Medical Center. The study looked at children between 6 ... years old in 2003-2004 and 2004-2005. The study found that, ...
... cause human blood and plasma to clota process that ... course of vertebrate evolution, according to new research at ... Infectious Diseases, and Institut Pasteur in Paris. Their findings ... Chemical Biology . , The discovery will improve scientists, ...
Cached Biology News:Red-eyed treefrog embryos actively avoid asphyxiation inside their eggs 2Flu shot protects kids -- even during years with a bad vaccine match 2Nature study demonstrates that bacterial clotting depends on clustering 2
Mycoplasma tested...
... SAGE (serial analysis of gene ... expression analysis. Expression profiles generated ... to detect low-abundance transcripts making ... genes. The I-SAGE Kit is ...
Human LAIR2 Biotinylated Affinity Purified PAb...
... The mycobacteria in ... cells to the injection site which enhances ... Freund's Adjuvant is used for the initial ... the subsequent boosts. Antigens (preferably in saline) ...
Biology Products: